Evaluation of Toxicity and Efficacy of 186Re-Hydroxyethylidene Diphosphonate in Patients with Painful Bone Metastases of Prostate or Breast Cancer

• Published in: The Journal of nuclear medicine (1978) Vol. 41; no. 10; pp. 1689 - 1694
• Main Authors: Kolesnikov-Gauthier, Helene, Carpentier, Philippe, Depreux, Pascal, Vennin, Philippe, Caty, Armel, Sulman, Charles
• Format: Journal Article
• Language: English
• Published: Reston, VA Soc Nuclear Med 01.10.2000; Society of Nuclear Medicine
• Subjects: Adenocarcinoma - pathology; Aged; Biological and medical sciences; Bone Neoplasms - radiotherapy; Bone Neoplasms - secondary; Breast Neoplasms - pathology; Diseases of the osteoarticular system; Diseases of the osteoarticular system. Orthopedic treatment; Etidronic Acid - therapeutic use; Etidronic Acid - toxicity; Female; Humans; Male; Medical sciences; Middle Aged; Organometallic Compounds; Palliative Care - methods; Prostatic Neoplasms - pathology; Radioisotopes - therapeutic use; Radioisotopes - toxicity; Radiopharmaceuticals - therapeutic use; Radiopharmaceuticals - toxicity; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects); Rhenium - therapeutic use; Rhenium - toxicity; Time Factors; Tumors of striated muscle and skeleton; Human; Urinary system disease; Prostate disease; Toxicity; Treatment efficiency; Diphosphonic acid derivatives; Metastasis; Malignant tumor; Radiotherapy; Mammary gland diseases; Phase II trial; Complication; Mammary gland; Bone; Rhenium; Male genital diseases; Prostate; Intractable pain
• ISSN: 0161-5505; 1535-5667

Twenty-eight patients (12 men with prostate cancer, 16 women with breast cancer) were included in a phase II trial to evaluate the efficacy of 186Re-hydroxyethylidene diphosphonate (HEDP) on pain from bone metastasis and the toxicity of this agent. After intravenous administration of 1295 MBq 186Re-HEDP, the efficacy was evaluated by means of a daily log. We observed an objective response in 67% of prostate cancer patients and in 36% of breast cancer patients. The mean duration of response was 45 d for prostate cancer patients and 24 d for breast cancer patients. No major adverse effects were observed. Marrow toxicity did not exceed grade 2 for white blood cells and grade 3 for platelets using National Cancer Institute criteria. 186Re-HEDP provides safe symptomatic relief of pain in prostate cancer patients. The benefit of this treatment is less clear in breast cancer patients. Further studies should be conducted to evaluate treatment by 186Re-HEDP at an earlier stage of the disease.